Litcius/Paper detail

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

Andrew Menzies‐Gow, Mark Gurnell, Liam G. Heaney, Jonathan Corren, Elisabeth H. Bel, Jorge Máspero, Timothy Harrison, David J. Jackson, David Price, Njira Lugogo, James L. Kreindler, Annie Burden, Alex De Giorgio-Miller, Kelly Padilla, Ubaldo J. Martin, Esther García Gil

2021The Lancet Respiratory Medicine174 citationsDOIOpen Access PDF

Topics & Concepts

MedicineBenralizumabAsthmaOpen labelCorticosteroidAlgorithmReduction (mathematics)DermatologyInternal medicineAdverse effectEosinophilGeometryComputer scienceMepolizumabMathematicsAsthma and respiratory diseasesAdrenal Hormones and DisordersDelphi Technique in Research
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study | Litcius